First and Only REN-Based Migraine Treatment Approved in China BEIJING and NETANYA, Israel, Sept. 29, 2025 /PRNewswire/ -- Pier 88 Health, a...
VANCOUVER, BC, Sept. 29, 2025 /CNW/ - Beautifi, Canada's leading medical financing provider, is proud to announce the launch of...
Insurtech acquisition unites next-gen AI-powered case design with proven compliance and operational infrastructure NEW YORK, Sept. 29, 2025 /PRNewswire/ --...
The addition of cardiology and neurology experts helps health companies scale evidence-based health products with confidence AUSTIN, Texas, Sept. 25,...
Late-breaking clinical data presented at the 41st Congress of the European Committee for Treatment and Research in Multiple Sclerosis Across non-active...
Seeking an indication for gait and balance deficit in patients with chronic symptoms of stroke under its Breakthrough Device DesignationNEWTOWN,...
A significant, dose-dependent reduction in bone marrow lesion presence and area was observed for LEVI-04 compared with placebo in patients...
Small-group EDI integration breaks market norms bringing automation and accuracy to ancillary benefits administration for groups of any size. INDIANAPOLIS, Sept....
VIENNA, Va., Sept. 24, 2025 /PRNewswire/ -- The National Academy of Elder Law Attorneys (NAELA) and the Special Needs Alliance...
During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every...
KYV-101 IIT data demonstrate promising clinical activity, including robust CAR T penetration into the central nervous system (CNS) and improved...
ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis...
OCREVUS subcutaneous maintains consistent benefit-risk profile after two years New late-breaking data confirms OCREVUS significantly reduces disability progression in adults...
WASHINGTON, Sept. 23, 2025 /PRNewswire/ -- As the medication experts, APhA affirms there has been no new evidence in two...
Study led by CureShankAims to characterize the direct and indirect burden of PMS to patients, caregivers, and US healthcare system...
Updates to McDonald Diagnostic Criteria for MS published NEW YORK, Sept. 18, 2025 /PRNewswire/ -- The McDonald Diagnostic Criteria for...
Once-daily oral brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement compared to placebo on the primary endpoint and...
PHILADELPHIA, PA / ACCESS Newswire / September 16, 2025 / TruMerit, a global leader in healthcare workforce development, today launched...
MIRA advances Ketamir-2 in the clinic for neuropathic pain while broadening development into neuropsychiatric disorders such as PTSD MIAMI, FLORIDA...
Clinical data shows that BrainsWay’s new accelerated stimulation protocol is comparable to standard Deep TMS in depression score improvement, response...